Inactivation of tumor-suppressor genes is one of the key hallmarks of a tumor. Unlike other tumor-suppressor genes, p53 is inactivated by missense mutations in half of all human cancers. It has become increasingly clear that the resulting mutant p53 proteins do not represent only the mere loss of wild-type p53 tumor suppressor activity, but gain new oncogenic properties favoring the insurgence, the maintenance, the spreading and the chemoresistance of malignant tumors. The actual challenge is the fine deciphering of the molecular mechanisms underlying the gain of function of mutant p53 proteins. In this review, we will focus mainly on the transcriptional activity of mutant p53 proteins as one of the potential molecular mechanisms. To date, the related knowledge is still quite scarce and many of the raised questions of this review are yet unanswered.
Introduction
Many proteins elicit their anti-cancer effects through the transcriptional activation of target genes, whose regulatory regions contain specific binding sites. Among them, a pivotal role in tumor suppression is played by the recently established p53 family. It consists of a group of proteins, whose oldest and the most studied member, p53, was identified more than 20 years ago (Lane and Crawford, 1979; Linzer and Levine, 1979; Oren and Levine, 1983; Beinz et al., 1984) , whereas its homologs p73 and p63 and their related and truncated spliced forms have been characterized in the last few years (Kaghad et al., 1997; Schmale, 1997; Osada et al., 1998; Senoo et al., 1998; Augustin et al., 1998; Trink et al., 1998; Yang et al., 1999) . The basic modular structure of p53 family members comprises a N-terminal transcriptional activation domain, a central DNA-binding domain and a C terminus with oligomeric and regulatory activities (McKinney and Prives, 2005) . The transcriptional activity of p53 family members is mainly regulated at the posttranslational level. Indeed, phosphorylation, acetylation, prolyl-isomerization and sumoylation are the most characterized post-translation modifications of p53 family members that impact on their transcriptional activity either by potentiating or dictating the selectivity in the activation of the proper target gene (Jayaraman and Prives, 1999; Costanzo et al., 2002; Brooks and Gu, 2003; Xu, 2003; Bode and Dong, 2004; Strano et al., 2005) . The net result of this selective transcriptional activation is the maximization of the efficacy of the anti-tumoral effects. To date, the set of p53 transcriptional target genes is also shared by p73 and p63.
As shown recently, it is conceivable that p73 and p63 can transcriptionally activate specific genes that are not target of wild-type (wt) p53 Blint et al., 2002; Kartasheva et al., 2003; Stiewe et al., 2003; Lapi et al., 2006) . This could represent, at least partially, the molecular basis of the different phenotypes of the respective p53 family members deficient mice. p53-deficient mice develop normally, but develop spontaneous tumors, mainly sarcomas and lymphomas (Jaks et al., 1994; Purdie et al., 1994; Donehower, 1996) . Conversely, p73 and p63 knockout mice exhibit severe developmental defects and do not spontaneously develop tumors (Mills et al., 1999; Yang et al., 1999 . Whereas p53 is mutated in almost half of all human cancers (http://.iarc.fr/p53), p73 and p63, despite extensive effort, have been found mutated very rarely in human tumors (Sunahara et al., 1998; Takahashi et al., 1998; Kaelin, 1999; Levrero et al., 2000; Yang and McKeon, 2000; Olivier et al., 2002) . Altogether, these findings indicate that among the p53 family members, p53 has been selected as a canonical tumor-suppressor gene whose inactivation certainly gives an advantage to the development and the maintenance of a cancer (Lowe et al., 2004) . Unlike other tumor-suppressor genes, whose inactivation results in the absence or in the presence of truncated proteins, p53 generates abundant full-length mutant proteins. This review aims to discuss some of the open questions regarding the origin and the function of mutant p53 proteins with a special focus on the transcriptional activity of human tumor-derived p53 gain of function mutants.
and Harris, 1998; Prives and Hall, 1999) . Mutant p53 proteins are abundantly present in cancer cells of various histotypes ranging from lung, colon, breast to some heamopoietic malignancies (Nigro et al., 1989; Soussi, 2000) . They are peculiarly characterized by a prolonged half-life compared with that of the wt-p53 protein and by the inability to recognize wt-p53 DNAbinding sites (Figure 1 ) (Sigal and Rotter, 2000; Cadwell and Zambetti, 2001) . The extent the half-life of mutant p53 varies among the diverse human tumor-derived p53 mutants. There is yet scarce evidence to allow a classification of mutant p53 proteins according to their specific half-life. The molecular basis of the prolonged half-life of mutant p53 proteins needs to be still understood. It might partially depend on the inefficient degradation exerted by the E3 ubiquitin ligase Mdm2, whose gene is a direct transcriptional target of wt-p53. Consequently, its activation is impaired in cells carrying mutant p53 proteins (Haupt et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997; Bushmann et al., 2000; Strano and Blandino, 2003; Lain and Lane, 2005) . Recent evidence derived from p53 knock-in mice have shown that mutant p53 proteins are unstable in normal tissues (Lang et al., 2004; Olive et al., 2004) . This strongly favors the hypothesis that the tumor cell context contains additional physical or chemical factors contributing to the increased half-life of mutant p53 proteins. The latter might be gathered in large and yet unknown protein complexes that make mutant p53 inaccessible to the protein degradation machinery. A certain contribution to the stability of mutant p53 could be also ascribed to its peculiar nuclear localization. Indeed, immunohistochemical analysis of tumor samples accompanied by gene sequence analysis have revealed extensive nuclear localization of mutant p53 proteins (Soussi, 2005) . As a consequence, the mechanisms regulating the nuclear/cytoplasmic shuttling of wt-p53, whose fine-tuning plays an important role on its stability, might be altered in cells bearing mutant p53 proteins (Moll et al., 1992; Moll and Petrenko, 2003) . Structural studies have allowed to classify p53 mutant proteins in two large categories (Cho et al., 1994; Bullock and Fersht, 2001; Joerger et al., 2005) : (a) DNA contactdefective mutants (His273, Trp248), which include those mutants whose mutation impacts on the residues composing the DNA/protein interaction surface and (b) structure-defective mutants (His175, His179), whose point mutation determines an important conformational alteration. The attempt to verify whether the structural classification of p53 mutants reveals similar differences in terms of biological activities has been quite difficult to tackle. In vitro studies have shown that the overexpression of conformational p53 mutants renders cell cultures more resistant to etoposide, whereas DNA defective mutants increases the resistance to cisplatin (Gualberto et al., 1998; Li et al., 1998; Blandino et al., 1999; Sigal and Rotter, 2000) . The presence of conformational mutants has been associated with breast cancer patients, whose relapse after conventional chemotherapy occurred more frequently when compared with patients carrying DNA contact defective p53 mutants (Aas et al., 1996; Berns et al., 2000; Geisler et al., 2003) . Altogether, these findings strongly indicate that mutant p53 proteins do not represent the mere loss of wt-p53 activities, but gain new additional oncogenic functions which contribute to the development, maintenance, spreading and resistance to anti-cancer treatment of a tumor. Given that some mutant p53 proteins exert a gain of function, the focus of intense research in the p53 field is the elucidation of the molecular mechanisms underlying this activity (Haley et al., 1990; Dittmer et al., 1993; Lin et al., 1995; Vousden and Lu, 2002; Monti et al., 2005) . To date, mutant p53 proteins might work through the following molecular scenarios: (a) mutant p53 interacts, sequesters and inactivates proteins whose activities are closely connected to anti-tumoral effects ranging from growth arrest to apoptosis induced by anti-cancer treatments. p73 and p63 have turned out to be protein targets of p53 gain-of-function mutants (Di Como et al., 1999; Marin et al., 2000) . Indeed, the binding to mutant p53 strongly defeats p73-and p63-mediated transcription and apoptosis (Strano et al., 2000; Irwin et al., 2003) . The in vivo recruitment of both p73 and p63 to the regulatory regions of their target genes is severely impaired in mutant p53-expressing cells. Of note, the core domain of mutant p53, that has been regarded as 'functional dead' due to its inability to recognize the wtp53-binding site, is sufficient for the binding to p73 and p63 (Gaiddon et al., 2001; Strano et al., 2002; Strano and Blandino, 2003) . Thus, it might serve as a proteinprotein interaction module, whose activity contributes to the gain of function. It is conceivable to believe that the identification of novel mutant p53-interacting proteins might allow, at least partially, the comprehension of the molecular mechanism underlying mutant p53 gain-of-function activity, and might disclose new therapeutic targets for innovative anti-cancer treatments; (b) Levine's group originally reported that p53 mutant, whose two critical residues at the N terminus were mutated, loses its gain-of-function activity (Lin et al., 1995) . Genome-wide approaches have shown that mutant p53 is capable of modulating the expression of large patterns of transcripts (Figure 2 ). These findings indicate that mutant p53 might function as a transcription factor capable to turn on and off specific set of genes in response to different stimuli (Margulies and Sehgal, 1993; Subler et al., 1994; Tsutsumi-Ishii et al., 1995; Ludes-Meyers et al., 1996; Deb et al., 1998; Frazier et al., 1998; Lee et al., 2000; Iwanaga and Jeang, 2002; Scian et al., 2004 Scian et al., , 2005 Mizuaray et al., 2006) . Consequently, mutant p53 might trigger different pathways that represent the molecular basis of the large spectrum of gain-of-function activities, which ranges from the resistance to anticancer treatments to genomic instability and increased metastasis. Despite rapidly accumulating evidence, the knowledge of the molecular details of the transcriptional activity of mutant p53 is still very scarce; (c) recent work by Di Agostino et al. Mutant p53: an oncogenic transcription factor S Strano et al mutant p53 is recruited in vivo to such regulatory regions through the physical interaction with the transcription factor NF-Y (Figure 3) . Altogether, these results show that the repertoire of the genes regulated by p53 gain-offunction mutants can be dictated by the specific interaction partner; (d) original work from Deppert's lab has shown that mutant p53 tightly associates with the nuclear matrix in vivo, and with high affinity with nuclear matrix attachment region DNA in vitro Koga and Deppert, 2000; Gohler et al., 2005; Kim and Deppert, 2006) . These findings suggest that mutant p53 interacting with key structural components of the nucleus exerts its gain-of-function activity through the perturbation of the nuclear structure and function. The molecular scenarios (c) and (d) suggest that the number of the potential transcriptional targets of mutant p53 could be quite large, and consequently the complexity of the triggered biochemical pathways considerably high.
Is mutant p53 a bona-fide transcription factor?
There is no exhaustive answer to this question. It represents the focus of intense research which to date has only produced some information and has left open many issues as discussed in this paragraph. Being accepted that wt-p53 is a well-known bona-fide transcription factor, whose specific DNA-binding consensus sequence, target genes and transcriptional signature have been identified, the reciprocal characterization for mutant p53 is still scarce.
DNA-binding consensus sequence
Chromatin immunoprecipitation (ChIP) experiments have recently and clearly shown that mutant p53 can be recruited in vivo onto regulatory regions of diverse genes (Weisz et al., 2004; Di Agostino et al., 2006; Zalcenstein et al., 2006) . Despite this, the question whether these genes are canonical transcriptional targets of p53 gain-of-function mutants is still unanswered. To date, the experimental efforts to identify a specific DNA-binding consensus sequence for mutant p53, if any exists, have failed. If mutant p53 is unable to bind directly to DNA, its presence onto promoter regions might occur as a member of large transcriptional competent protein complexes. Recent evidence indicates that mutant p53 is present onto promoter regions together with DNA-binding proteins, acetylases and/ or deacetylases (Di Agostino et al., 2006) . The selective recruitment of acetylates or deacetylates in response to DNA damage dictates transcriptional activation or repression of target genes (Figure 3) . Further Figure 3 The mutant p53/NF-Y connection. In response to DNA damage, the protein complex mutant p53-NFY recruits p300 and assembles on the promoters of NF-Y target genes.
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Mutant p53: an oncogenic transcription factor S Strano et al experimental work through sequential re-ChIP will eventually confirm the existence of mutant p53 containing transcriptional competent complexes onto regulatory regions of target genes. The type of mutant p53 functional contribution to the activity of the transcriptional competent complex is under intense investigation. Mutant p53 could take part into the transcriptional core of the complex through its intact N terminus, or alternatively by favoring the recruitment of other members required for the transcriptional activity of the protein complex. Recent evidence shows that mutant p53 is necessary for the recruitment of p300 to the transcriptional competent complex (Di Agostino et al., 2006) . Although many evidences have clearly shown that post-translational modifications such as serine/ threonine phosphorylation, acetylation, prolylisomerization and sumoylation increase the DNA-binding and the transcriptional activity of wt-p53 (Bode and Dong, 2004) , the impact of these events on mutant p53 transcriptional activity has been evaluated poorly.
Pattern of target genes
Microarray analyses have shown that the overexpression of mutant p53 in different cell lines is capable to modulate the expression of many transcripts (Hoh et al., 2002; O'Farrel et al., 2004; Scian et al., 2004; Weisz et al., 2004; Tepper et al., 2005; Zalcenstein et al., 2006) . Although a growing pattern of target genes has been established for wt-p53 and other transcription factors closely linked to cancer, the definition of a group of potential mutant p53 target genes needs to be solved yet. The issue is very difficult to tackle due to the heterogeneity of p53 mutants, each one of which potentially could represent a specific transcription factor activating a peculiar pattern of genes only partially overlapping with that of other gain of function p53 mutants. A comparative bioinformatical analysis of the existing microarray data for mutant p53 might be very helpful to identify a restricted pattern of genes whose modulation could be further investigated in diverse cell contexts carrying mutant p53.
Transcriptional signature
There is growing evidence that ChIP on chip is a very powerful technology that allows genome-wide evaluation of in vivo promoter occupancy by a certain transcription factor (Wu et al., 2006) . The application of this technique could be extremely useful for a further establishment of the transcriptional activity of p53 gainof-function mutants. Indeed, mutant p53-immunoprecipitated chromatin derived from diverse cancer cell lines might be used to probe genome-wide promoter chips as well as low density and promoters-oriented chips (Buck and Lieb, 2004) . The analysis of genome-wide promoter chips will allow the identification of novel transcriptional target genes whose regulatory regions are bound in vivo by mutant p53. The results raised through the analysis of low-density promoter-oriented chips might allow the validation of a mutant p53 transcriptional signature to be tested in different cancer cell contexts carrying diverse human tumor-derived p53 mutants and upon different types of stimuli.
Perspectives
There is sufficient evidence in vitro and in vivo to establish an oncogenic role for some human tumorderived p53 mutants (Lang et al., 2004; Olive et al., 2004; Di Agostino et al., 2006) . As p53 mutants are present in almost half of human cancers, the possibility to tackle and abolish their oncogenic effects is undoubtedly important for a successful treatment of human tumors. To fulfil such objective, a detail knowledge of the molecular mechanisms underlying gain of function of mutant p53 is a necessary step. Among them, the comprehension of the transcriptional activity of mutant p53 will contribute to unveil biochemical pathways whose selective targeting might turn out very useful for the treatment of mutant p53 human cancers.
